Literature DB >> 2665838

Production of interleukin-1 by bone marrow myeloma cells.

F Cozzolino1, M Torcia, D Aldinucci, A Rubartelli, A Miliani, A R Shaw, P M Lansdorp, R Di Guglielmo.   

Abstract

Plasma cells isolated from bone marrow (BM) aspirates of 12 patients with multiple myeloma (MM) and nine patients with monoclonal gammopathy of undetermined significance (MGUS) were analyzed for production of cytokines with bone-resorbing activity, such as interleukin-1 (IL-1), tumor necrosis factor (TNF), and lymphotoxin (LT). Culture supernatants of plasma cells from MM, but not from MGUS or normal donor, invariably contained high amounts of IL-1-beta and lower amounts of IL-1-alpha. With a single exception, TNF/LT biologic activity was not detected in the same supernatants. IL-6 was present in two of five supernatants tested. Normal B lymphocytes released both IL-1 and TNF/LT activities for four days after activation in vitro; however, production of these cytokines ceased at the final stage of plasma cell. Unexpectedly, the mRNA extracted from MM plasma cell hybridized with TNF- and LT-specific, as well as IL-1-specific probes, although the culture supernatants did not contain detectable TNF/LT biologic activity. When tested in the fetal rat long bone assay, MM plasma cell supernatants displayed a strong osteoclast-activating factor (OAF) activity, which was greatly reduced but not completely abolished by neutralizing anti-IL-1 antibodies. Anti-TNF or anti-LT antibodies were ineffective in the same test. We conclude that the IL-1 released in vivo by malignant plasma cells has a major role in pathogenesis of lytic bone lesions of human MM.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665838

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Peripheral polyneuropathy associated with multiple myeloma.

Authors:  G Lipponi; P M Gasparrini; C Lucantoni; G Cadeddu; R Gaetti
Journal:  Ital J Neurol Sci       Date:  1992-09

2.  Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.

Authors:  D M Nachbaur; M Herold; A Maneschg; H Huber
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

Review 3.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

Authors:  M Jourdan; K Tarte; E Legouffe; J Brochier; J F Rossi; B Klein
Journal:  Eur Cytokine Netw       Date:  1999-03       Impact factor: 2.737

6.  Cytokines involved in the progression of multiple myeloma.

Authors:  F Merico; L Bergui; M G Gregoretti; P Ghia; G Aimo; I J Lindley; F Caligaris-Cappio
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

7.  Endoplasmic reticulum stress induces a caspase-dependent N-terminal cleavage of RBX1 protein in B cells.

Authors:  Shimon Shteingart; Rivka Hadar; Itamar Cohen; Tommer Ravid; Boaz Tirosh
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

8.  Mast cell and macrophage counts and microvessel density in invasive breast carcinoma-comparison analysis with clinicopathological parameters.

Authors:  Gui Young Kwon; Sang Dae Lee; Eon Sub Park
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

Review 9.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

Review 10.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.